[go: up one dir, main page]

BR9702080A - Sequências de codificação do gene brca1 humano - Google Patents

Sequências de codificação do gene brca1 humano

Info

Publication number
BR9702080A
BR9702080A BR9702080-0A BR9702080A BR9702080A BR 9702080 A BR9702080 A BR 9702080A BR 9702080 A BR9702080 A BR 9702080A BR 9702080 A BR9702080 A BR 9702080A
Authority
BR
Brazil
Prior art keywords
brca1
coding sequences
gene
brca1 gene
sequences
Prior art date
Application number
BR9702080-0A
Other languages
English (en)
Inventor
Patricia D Murphy
Antonette C Allen
Christopher P Alvares
Brenda S Critz
Sheri J Olson
Denise B Schelter
Bin Zeng
Original Assignee
Oncormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24396174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9702080(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncormed Inc filed Critical Oncormed Inc
Publication of BR9702080A publication Critical patent/BR9702080A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"SEQuêNCIAS DE CONDIFICAçãO DO GENE BRCA1 HUMANO". Seq³ências de codificação isoladas e as seq³ências de proteínas que elas codificam. Esta invenção é dirigida a três seq³ências de codificação de gene BRCA1. As três seq³ências de codificação, BRCA1^ (omi1)^, BRCA1 ^(omi2) e BRCA1 ^ (omi3)^ e suas freq³ências de ocorrências são providas juntas com as seq³ências de proteína que elas codificam. Outro aspecto da invenção é um processo para determinar a seq³ência de consenso para este gene. Outro aspecto da invenção é um processo para identificar um indivíduo tendo uma aumentada suscetibilidade genética para câncer do ovário e mama porque eles herdaram uma mutação que provoca o mesmo em seu gene BRCA1. Esta invenção é também relacionada com um processo para realizar a terapia genética com qualquer uma das seq³ências de codificação de BRCA1 isoladas.
BR9702080-0A 1996-02-12 1997-02-12 Sequências de codificação do gene brca1 humano BR9702080A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/598,591 US5654155A (en) 1996-02-12 1996-02-12 Consensus sequence of the human BRCA1 gene
PCT/US1997/003038 WO1997029213A1 (en) 1996-02-12 1997-02-12 Coding sequences of the human brca1 gene

Publications (1)

Publication Number Publication Date
BR9702080A true BR9702080A (pt) 1999-12-28

Family

ID=24396174

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9702080-0A BR9702080A (pt) 1996-02-12 1997-02-12 Sequências de codificação do gene brca1 humano

Country Status (14)

Country Link
US (2) US5654155A (pt)
EP (3) EP1126034A3 (pt)
JP (2) JPH11503924A (pt)
AT (1) ATE208425T1 (pt)
AU (1) AU1977897A (pt)
BR (1) BR9702080A (pt)
CA (1) CA2218251C (pt)
DE (1) DE69707985T2 (pt)
DK (1) DK0820526T3 (pt)
ES (1) ES2170366T3 (pt)
IL (1) IL121926A (pt)
IS (1) IS4587A (pt)
PT (1) PT820526E (pt)
WO (1) WO1997029213A1 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403303B1 (en) * 1996-05-14 2002-06-11 Visible Genetics Inc. Method and reagents for testing for mutations in the BRCA1 gene
US5747282A (en) * 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
US6083698A (en) * 1995-09-25 2000-07-04 Oncormed, Inc. Cancer susceptibility mutations of BRCA1
US20030022184A1 (en) * 1996-02-12 2003-01-30 Oncormed. Inc. Coding sequences of the human BRCA1 gene
US5654155A (en) * 1996-02-12 1997-08-05 Oncormed, Inc. Consensus sequence of the human BRCA1 gene
US6838256B2 (en) 1996-02-12 2005-01-04 Gene Logic Inc. Coding sequences of the human BRCA1 gene
US6130322A (en) * 1996-02-12 2000-10-10 Gene Logic, Inc. Coding sequences of the human BRCA1 gene
US6951721B2 (en) * 1996-02-12 2005-10-04 Gene Logic Inc. Method for determining the haplotype of a human BRCA1 gene
US5891857A (en) * 1996-02-20 1999-04-06 Vanderbilt University Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins
CA2198801A1 (en) * 1996-02-29 1997-08-29 Catherine M. Phelan Method and kit for evaluating risk of ovarian cancer in carriers of brc a1 mutation
WO1998001460A1 (en) * 1996-07-08 1998-01-15 Board Of Regents, The University Of Texas System Brca1 compositions and methods for the diagnosis and treatment of breast cancer
AU4586697A (en) * 1996-09-20 1998-04-14 Board Of Regents, The University Of Texas System Compositions and methods comprising bard1 and other brca1 binding proteins
WO1998018966A1 (en) * 1996-10-31 1998-05-07 Jennifer Lescallett Primers for amplification of brca1
US6048689A (en) * 1997-03-28 2000-04-11 Gene Logic, Inc. Method for identifying variations in polynucleotide sequences
EP0878552A1 (en) * 1997-05-13 1998-11-18 Erasmus Universiteit Rotterdam Molecular detection of chromosome aberrations
WO1999006598A2 (en) * 1997-08-04 1999-02-11 Oncormed, Inc. Determining common functional alleles in a population and uses therefor
US20090269814A1 (en) * 1998-05-22 2009-10-29 Murphy Patricia D Method of Analyzing a BRCA2 Gene in a Human Subject
WO1999015704A1 (en) * 1997-09-23 1999-04-01 Oncormed, Inc. Genetic panel assay for susceptibility mutations in breast and ovarian cancer
US6492109B1 (en) 1997-09-23 2002-12-10 Gene Logic, Inc. Susceptibility mutation 6495delGC of BRCA2
US6030832A (en) 1997-11-21 2000-02-29 Myriad Genetics, Inc. Carboxy-terminal BRCA1 interacting protein
US6177410B1 (en) 1997-12-05 2001-01-23 Vanderbilt University Therapeutic methods for prostate cancer
US6897018B1 (en) * 1998-02-25 2005-05-24 The United States Of America As Represented By The Department Of Health And Human Services DLC-1 gene deleted in cancers
WO1999057309A1 (en) * 1998-05-04 1999-11-11 Dako A/S Method and probes for the detection of chromosome aberrations
US6686163B2 (en) * 1998-05-06 2004-02-03 Gene Logic Inc. Coding sequence haplotype of the human BRCA1 gene
BR9911882A (pt) 1998-07-13 2005-02-15 Univ Texas Processo de tratamento de câncer empregando anticorpos a aminofosfolipìdios
SI1107795T1 (en) 1998-09-04 2003-06-30 The Regents Of The University Of Michigan Thiomolybdate associated with at least one carbohydrate, and its use for preventing or treating diseases characterized by aberrant vascularization, such as cancer, wet type macular degeneration, rheumatoid arthritis
US20030180789A1 (en) * 1998-12-30 2003-09-25 Dale Roderic M.K. Arrays with modified oligonucleotide and polynucleotide compositions
US6087112A (en) * 1998-12-30 2000-07-11 Oligos Etc. Inc. Arrays with modified oligonucleotide and polynucleotide compositions
US20060121463A1 (en) * 2002-06-06 2006-06-08 The John Hopkins University Allelic variation in human gene expression
NZ574146A (en) 2002-07-15 2010-05-28 Univ Texas Peptides binding to phosphatidylethanolamine and their use in treating viral infections
TWI304321B (en) 2002-12-27 2008-12-11 Toray Industries Layered products, electromagnetic wave shielding molded articles and method for production thereof
US8431396B2 (en) 2003-03-21 2013-04-30 The Cleveland Clinic Foundation Anti-angiogenic peptides
AU2003301503A1 (en) * 2003-12-16 2005-07-14 Centre National De La Recherche Scientifique Methods and compositions for assaying mutations in nucleic acids
BRPI0507039A8 (pt) 2004-01-22 2018-12-18 Univ Miami composição, métodos de tratar um paciente com câncer, e de inibir a angiogênese em um tumor, e, kit
EA034136B1 (ru) 2007-11-09 2020-01-09 Перигрин Фармасьютикалз, Инк. Изолированное антитело, которое связывается с vegf, и его применения
ES2574137T3 (es) * 2008-09-03 2016-06-15 Quantumdx Group Limited Estrategias y métodos de detección de ácidos nucleicos mediante biosensores
WO2010059233A2 (en) 2008-11-21 2010-05-27 Morehouse School Of Medicine Application for letters patent
JP2014532403A (ja) 2011-10-31 2014-12-08 ゲノミク ビジョン ゲノムモールスコードを分子コーミングと併用する乳癌及び卵巣癌遺伝子並びに遺伝子座ｂｒｃａ１及びｂｒｃａ２におけるゲノム再編成の検出、可視化、及び高解像度物理マッピングの方法
WO2014140788A1 (en) 2013-03-15 2014-09-18 Genomic Vision Methods for the detection of sequence amplification in the brca1 locus
WO2014140789A1 (en) 2013-03-15 2014-09-18 Genomic Vision Methods for the detection of breakpoints in rearranged genomic sequences
EP3839974B9 (en) 2019-12-20 2023-05-03 Dynamic Code AB Method for analysing the likelihood of diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US5221619A (en) 1977-11-08 1993-06-22 Genentech, Inc. Method and means for microbial polypeptide expression
US5583013A (en) 1977-11-08 1996-12-10 Genentech, Inc. Method and means for microbial polypeptide expression
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5593840A (en) 1993-01-27 1997-01-14 Oncor, Inc. Amplification of nucleic acid sequences
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
ATE201445T1 (de) * 1994-08-12 2001-06-15 Myriad Genetics Inc Mutationen des mit 17q verbundenen ovarial- und brustkrebs empfindlichkeitsgens
US5693473A (en) * 1994-08-12 1997-12-02 Myriad Genetics, Inc. Linked breast and ovarian cancer susceptibility gene
AU691331B2 (en) * 1994-08-12 1998-05-14 Myriad Genetics, Inc. Method for diagnosing a predisposition for breast and ovarian cancer
US5654155A (en) * 1996-02-12 1997-08-05 Oncormed, Inc. Consensus sequence of the human BRCA1 gene

Also Published As

Publication number Publication date
IS4587A (is) 1997-10-10
DE69707985D1 (de) 2001-12-13
CA2218251A1 (en) 1997-08-14
JPH11503924A (ja) 1999-04-06
EP0820526B1 (en) 2001-11-07
CA2218251C (en) 2010-10-19
US5750400A (en) 1998-05-12
IL121926A0 (en) 1998-03-10
PT820526E (pt) 2002-05-31
EP0820526A1 (en) 1998-01-28
EP0820526A4 (en) 1998-07-08
EP2351854A1 (en) 2011-08-03
AU1977897A (en) 1997-08-28
ATE208425T1 (de) 2001-11-15
US5654155A (en) 1997-08-05
DE69707985T2 (de) 2002-10-31
JP2012090627A (ja) 2012-05-17
EP1126034A2 (en) 2001-08-22
DK0820526T3 (da) 2002-03-04
WO1997029213A1 (en) 1997-08-14
EP1126034A3 (en) 2001-08-29
ES2170366T3 (es) 2002-08-01
IL121926A (en) 2006-08-01

Similar Documents

Publication Publication Date Title
BR9702080A (pt) Sequências de codificação do gene brca1 humano
DK0858467T3 (da) Materialer og fremgangsmåder angående identifikationen og sekventeringen af BRCA2 cancerfölsomhedsgen og anvendelser deraf
CY1106216T1 (el) 5´ ESTs ΓΙΑ ΜΗ ΙΣΤΟ-ΕΙΔΙΚΕΣ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
FI970514A0 (fi) 17q:hun liittyvä rinta- ja munasarjasyöpäalttiusgeeni
ATE435281T1 (de) Im cadasil bezogenes gen, diagnostikums-verfahren und therapeutische verwendung
NO970624D0 (no) In vivo mutasjoner og polymorfismer i 17q-koblete bryst-og ovariekreft mottagelighetsgener
ATE309536T1 (de) Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen
DK1295944T3 (da) GDP-dissociationsstimulerende protein, hjernespecifikt nukleosomsamlingsprotein, skeletmuskelspecifikt ubiquitinkonjugerende enzym, celleproliferationsprotein, phosphatidylinositolkinase, nelbeslægtede proteiner
DE69637156D1 (de) Dna-molekül, herstellung und verwendung in der gentherapie
AU2003293141A8 (en) Methods for identifying risk of breast cancer and treatments thereof
HUP0004326A2 (hu) A tumor-szupresszor génterápia és a kemoterápia kombinálása a daganatok kezelésében
PT81624B (pt) Metodos recombinantes para a producao de inibidores da protease serina e metodos para o isolamento dos mesmos
CY1105398T1 (el) 5΄ ESTs ΓΙΑ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ ΠΟΥ ΕΚΦΡΑΖΟΝΤΑΙ ΣΕ ΔΙΑΦΟΡΟΥΣ ΙΣΤΟΥΣ
ATE307886T1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
DE69605908D1 (de) Benutzung von reagenzien abgeleitet vom menschlichen metastase unterdrückungs gen kai1 in diagnostischen und gen-terapeutischen verfahren
EP0756488A4 (en) TUMOR SUPPRESSOR GENE AND METHOD FOR DETECTING CANCER
EP1100815A4 (en) PROTEASE TYPE II CLEAVABLE PEPTIDE
ATE517122T1 (de) Modifizierte cea-nukleinsäure und entsprechende expressionsvektoren
CY1111522T1 (el) 84p2a9: ειδικη σε προστατη και ορχεις πρωτεϊνη που εκφραζεται σε υψηλο βαθμο στον προστατικο καρκινο
WO2000008157A3 (en) Human anion transporter genes atnov
ATE170561T1 (de) Methode und zusammensetzungen zur behandlung von bösartigen entartungen, die in zusammenhang mit einer proteinkinase stehen
HUP9900011A2 (hu) A GAX protein alkalmazása rák kezelésére
ATE267611T1 (de) MENSCHLICHES ßMINOR VAULTß PROTEIN P193
DK0950062T3 (da) Proteinmarkörer for esophageal cancer

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: O DEPOSITANTE DEIXOU DE APRESENTAR MANIFESTACAO SOBRE O PARECER NEGATIVO, ASSIM, DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR.